Results 181 to 190 of about 617 (209)

S54 Inflammatory Bowel Disease Unmasked by Interleukin-17 Inhibitor for Psoriasis

American Journal of Gastroenterology, 2023
Jake Wilson, Erin Forster
openaire   +1 more source

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

European Journal of Medicinal Chemistry, 2023
Hong-Min Liu, Sai-Qi Wang, Dan-Dan Shen   +2 more
exaly  

5PSQ-093 Persistence of treatment with interleukin -17 inhibitors in skin disorders

Section 5: Patient safety and quality assurance, 2022
C Pastor Mondéjar, C Iniesta Navalón, A Martínez Soto, P Ortiz Fernández, P Ferandez-Villacañas Ferandez, I Salar Valverde, L Rentero Redondo, C Caballero Requejo, M Garcia Coronel, E Urbieta Sanz   +9 more
openaire   +1 more source

Interleukin 17 inhibitors

Reactions Weekly
openaire   +2 more sources

Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review

Frontiers in Immunology, 2022
Gokhan Keser, Pamir Atagunduz, Mehmet Soy   +2 more
exaly  

Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12

Journal of Dermatological Treatment, 2022
Christopher Schuster, Diamant Thaçi, Alice Gottlieb   +2 more
exaly  

Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?

Neurological Sciences, 2023
Sohyeon Kim, Mi-Yeon Eun, Hung Youl Seok
openaire   +3 more sources

Interleukin‐17 inhibitors for the management of severe rosacea

Australasian Journal of Dermatology
Sera Sarsam, Dédée F. Murrell
openaire   +2 more sources

Efficacy and safety of interleukin‐17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta‐analysis

Journal of Clinical Pharmacy and Therapeutics, 2021
Luo Yue, Pengde Kang
exaly  

Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis

Chinese Journal of Dermatology, 2022
openaire   +1 more source